| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2011-04-14 | DCOne (dendritic cell-based cancer vaccine) | acute myeloid leukemia | 1 | DCPrime (The Netherlands) | Cancer - Oncology |
| 2011-04-13 | Yondelis® (trabectedin) | breast cancer | 2 | PharmaMar (Spain) | Cancer - Oncology |
| 2011-04-11 | V170 | Staphylococcus aureus infection | 2-3 | Merck&Co (USA) Intercell (Austria) | Infectious diseases |
| 2011-04-11 | Tasigna® (nilotinib) | first-line treatment of gastrointestinal stromal tumors |
3 | Novartis (Switzerland) | Cancer - Oncology |
| 2011-04-11 | NP2 Enkephalin | intractable cancer pain | 1 | Diamyd (Sweden) | Cancer - Oncology - CNS diseases |
| 2011-04-07 | solnatide - AP301 - synthetic peptide L-cysteine, L-cysteinylglycyl-L-glutaminyl-L-arginyl-L-.alpha.-glutamyl-Lthreonyl-L-prolyl-L-.alpha.-glutamylglycyl-L-alanyl-L-.alpha.-glutamyl-L-alanyl-L-lysyl-L-prolyl-Ltryptophyl-L-tyrosyl-,cyclic (1.fwdarw.17)-disulfide | pulmonary edema | 1 | Apeptico (Austria) | Respiratory diseases |
| 2011-04-07 | trastuzumab emtansine (T-DM1) | HER2-positive metastatic breast cancer | 2 | Roche (Switzerland) | Cancer - Oncology |
| 2011-04-07 | alemtuzumab | multiple sclerosis |
2 | Genzyme (USA -MA), a Sanofi company (France) | Autoimmune diseases - Neurodegenerative diseases |
| 2011-04-06 | JX-594/TG6006 (Pexa-Vec) | refractory solid tumors | 1 | Transgene (France) Jennerex (USA) | Cancer - Oncology |
| 2011-04-05 | Cyclokat® (cyclosporine ophthalmic formulation) | dry eye disease | 3 | Novagali Pharma (France) | Ophtalmological diseases |
| 2011-04-05 | mipomersen | heterozygous familial hypercholesterolemia | 3 | Genzyme (USA - MA), a Sanofi company (France) | Cardiovascular diseases - Genetic diseases - Rare diseases |
| 2011-04-05 | mipomersen | high cholesterol at high risk for CHD |
3 | Genzyme (USA - MA), a Sanofi company (France) | Cardiovascular diseases |
| 2011-04-05 | alemtuzumab | multiple sclerosis |
2 | Genzyme (USA - MA), a Sanofi company (France) | Autoimmune diseases - Neurodegenerative diseases |
| 2011-04-05 | Xarelto® (rivaroxaban) | prevention of venous thromboembolism (VTE) in hospitalized patients with acute medical illness |
3 | Bayer Healthcare (Germany) | Cardiovascular diseases |
| 2011-04-05 | JX-594/TG6006 (Pexa-Vec) | hepatocellular carcinoma | 1-2 | Transgene (France) Jennerex (USA) | Cancer - Oncology |
| 2011-04-04 | EHT 0202 | Alzheimer’s disease | 2a | Exonhit Therapeutics (France) | Neurodegenerative diseases |
| 2011-04-04 | TX-RAD (type 1 regulatory T cell based immunotherapy) | rheumatoid arthritis | 1-2 | TxCell (France) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2011-04-02 | BI 201335 | hepatitis C |
3 | Boehringer Ingelheim (Germany) | Infectious diseases |
| 2011-03-31 | Locteron® (controlled-release interferon alpha ) | hepatitis C genotype 1 virus (HCV) |
2b | OctoPlus (The Netherlands) Biolex Therapeutics (USA) | Infectious diseases |
| 2011-03-31 | DEB025 (alisporivir) | chronic hepatitis C |
2 | Novartis (Switzerland) | Infectious diseases |
